In developing liposomes for in vivo use, it is important to design the liposomes to have
optimal in vivo kinetics, and it is also necessary to identify optimal high-throughput …

Nattokinase (NK), a potent thrombolytic enzyme that dissolves blood clots, is highly used in
the treatment of cardiovascular disorders. However, its effective delivery remains demanding …

Liposomes have been extensively explored as drug carriers, but their clinical translation has
been hampered by their low drug-loading content and premature leakage of drug payloads …

Background: Current thrombolytic therapies utilize exogenous plasminogen activators (PAs)
to effectively lyse clots, restoring blood flow, and preventing tissue and organ death. These …

Local drug delivery has become an important treatment modality for the prevention of
thrombotic events following coronary angioplasty. In this study, we investigate the ability of …

Activated platelets play multiple roles in vascular diseases. Hence, a delivery vehicle that
can specifically target activated platelets and stay retained under a hemodynamic …

Intravenous administration of fibrinolytic drugs is the standard treatment of acute thrombotic
diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short …

The haemolysis caused by various types of liposomes was measured after incubation of
liposomes with human red blood cell (erythrocyte) suspension. Liposomes composed of …

Tissue plasminogen activator (tPA) is the sole approved therapeutic molecule for the
treatment of acute ischemic stroke. Yet, only a small percentage of patients could benefit …

A thrombus is a blood clot that forms in the lumen of an artery or vein, restricting blood flow
and causing clinical symptoms. Thrombosis is associated with many life‐threatening …